TRAIL selectively induces apoptosis in a variety of tumor cells, whereas majority of normal cells remain unresponsive to its effect. This unique capacity has placed TRAIL in the forefront as a promising anti-cancer agent. Unfortunately, resistance to TRAIL is not uncommon as TRAIL resistance can be developed by several mechanisms. DARPP-32 is frequently overexpressed in a number of human malignancies including adenocarcinomas of the colon, pancreas, breast, esophageal, and gastric. In this study, we used gastric cancer models and identified DARPP-32 as a major mediator of TRAIL resistance. Our findings provide novel insight in understanding the complexity of TRAIL resistance which could be applicable to other cancers. These findings can guide the development of therapeutic management approaches to circumvent apoptotic blockades or suppress survival signals.
Introduction
Gastric cancer is one of the most frequent malignancies worldwide (1, 2) . Although various chemotherapeutic drugs have been utilized, drug resistance has significantly hampered the effectiveness of chemotherapy leading to poor survival rates in patients with gastric cancer (3, 4) .
Death receptor-mediated cell death is one of the major apoptosis pathways. Death receptors including DR4 and DR5, relay a death signal upon binding with tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) (5, 6) , which shares protein homology with Fas ligand and TNFɲ (7) . Upon treatment with TRAIL, the initiator procaspase 8 is recruited to death receptors through the adaptor protein FADD, forming the death-inducing signaling complex (DISC). This results in autocatalytic activation of caspase 8 that directly activates caspase 3 and apoptosis in type I cells. However, in type II cells, caspase 8 through cleavage of Bid activates the intrinsic mitochondrial apoptosis pathway, which is mediated by cytochrome c release and activation of caspases 9 and 3 (8) (9) (10) . TRAIL selectively induces apoptosis in a variety of tumor cells, whereas several normal cells remain unresponsive to its effects (11, 12) . This unique capacity has placed TRAIL in the forefront as a promising anti-cancer agent. Unfortunately, resistance to TRAIL is not uncommon as TRAIL resistance can be developed by several mechanisms; for instance, overexpression of BCL-xL in type II cells has been shown to protect against TRAIL-mediated apoptosis through inhibition of the intrinsic pathway (13, 14) . Several -6 -xL in cancer cells (reviewed by Grad et al. (15) ). FLIP, which resembles caspase 8 but lacks the enzymatic activity, competes with caspase 8 to bind to FADD, thereby inhibiting TRAIL-induced death receptor signaling (16) . Increased expression of FLIP has been shown to promote resistance of cancer cells to death receptor-mediated apoptosis (17) . In addition, expression of FLIP(S) completely inhibited TRAIL-induced apoptosis through blocking activation of caspase 8 in gastric cancer cells, and AKT activity promoted cancer cell survival through up-regulation of FLIP(S) (18) .
The FLIP gene is regulated by several anti-apoptotic pathways including the AKT, MAPK, and NF-kB pathways (19, 20) .
We have previously reported that dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) is amplified and overexpressed in about two-thirds of upper gastrointestinal adenocarcinomas (21) . We demonstrated that DARPP-32 expression was associated with the multistep gastric carcinogenesis cascade involving the transition to intestinal metaplasia and the progression to neoplasia (22) . Little is known about the mechanisms of TRAIL resistance in gastric cancer. In the current study, we uncovered a novel mechanism by which DARPP-32 blocks TRAILinduced apoptosis in gastric cancer cells.
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Materials and methods

Cell lines and reagents
The human gastric cancer cell lines, MKN-28 and MKN-45, were maintained in culture using Dulbecco's modified Eagle's medium (GIBCO, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, CA) and 1% penicillin/streptomycin (GIBCO).
Recombinant human TRAIL/Apo2 ligand was purchased from BioVision Research Products (Mountain View, CA). 4-Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo [3,4- 
DARPP-32 expression and shRNA vectors
The mammalian expression plasmid for DARPP-32 was produced by PCR amplification of the full-length coding sequence of DARPP-32 and cloned in-frame into pcDNA3 (Invitrogen). MKN-28 cells stably expressing DARPP-32 or pcDNA3 empty vector were generated following standard protocols as previously described (21) . After selection with 500 μg/ml neomycin (G418) (Invitrogen), DARPP-32 protein expression was evaluated by Western blot analysis and clones were selected. Lentivirus particles expressing DARPP-32 shRNA or control shRNA were produced by GeneCopoeia (Rockville, MD) and then utilized to transduce cells.
Clonogenic survival assay
Cells were first washed with PBS, trypsinized, and harvested in single cell suspension. Cells (1000 cells per well) were seeded onto 6-well plates. The next day, cells were treated for 24h with TRAIL or vehicle. After incubation for two weeks, colonies were fixed with 4% paraformaldehyde and stained with 0.05% crystal violet. Colonies with ш50 cells were counted. Alternatively, the long-term cell viability was determined using the Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega) following the supplier's instructions. 
Apoptosis assay
MKN
Immunofluorescence assay
To evaluate cytochrome c release, MKN-28 cells stably expressing DARPP-32 or pcDNA3 empty vector were treated with 200 ng/ml TRAIL or vehicle for 24h. Immunofluorescence was performed with anti-cytochrome c antibody (1:200) and a secondary antibody conjugated to TRITC (1:800), as described previously (23) . The cells were examined by fluorescence microscopy (Olympus America Inc., Center Valley, PA). In healthy cells, cytochrome c was depicted by punctuated red fluorescence. In apoptotic cells, cytochrome c release was indicated by diffused
Research. -9 -red staining. 4', 6-Diamidino-2-phenylindole (DAPI) was used as a nuclear counterstain (blue fluorescence). The ratio of cells that presented diffused cytochrome c staining to the total number of cells was averaged from six random microscopic fields for more than 100 cells in each category.
To assess NF-kBp65 nuclear localization, MKN-28 cells stably expressing DARPP-32 or pcDNA3 empty vector, were treated with 200 ng/ml TRAIL or vehicle for 24h. Cells were subjected to immunofluorescence assay with anti-NF-kBp65 antibody (1:200) and a secondary antibody conjugated to FITC (1:800). DAPI was used as a nuclear counterstain. The cells were visualized by fluorescence microscopy. The ratio of cells that presented nuclear NF-kBp65 staining (indicating activation of NF-kB) to the total number of cells was averaged from five random microscopic fields for more than 100 cells in each category.
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR was performed in triplicate using an iCycler (Bio-Rad) with a threshold cycle number determined by use of iCycler software version 3.0. Total RNA was isolated from cells using an RNeasy Mini Kit (Qiagen, Valencia, CA). Single-stranded cDNA was synthesized from a total RNA amount of 1 μg by an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). mRNA specific primers for FLIP(L), FLIP(S), BCL-xL, and HPRT1 were designed, and the results were normalized to HPRT1 as a stable reference gene for quantitative real-time RT-PCR. All primer sequences are available upon request. The mRNA fold expression levels were calculated according to the formula 2 (RT-ET) /2 (Rn-En) , as described previously (24) .
Western blot analysis
Cell lysates were prepared in 0.5% Triton X-100, 150 mM NaCl, 5 mM -10 -using a Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA). Proteins (10-20 μg) from each sample were separated on 10% SDS-PAGE and transferred to Immobilon PVDF membrane (Millipore, Billerica, MA). Membranes were probed with specific antibodies, and proteins were visualized by using horseradish peroxidase (HRP)-conjugated secondary antibodies and Immobilon Western Chemiluminescent HRP Substrate detection reagent (Millipore). Gel loading was normalized for equal ɴ-actin.
Luciferase reporter assay
To assess the activity of the NF-kB signaling pathway, we used the NF-kB-Luc reporter vector that contains multiple copies of the consensus sequence (Clontech). After endogenous NFkB proteins bind to the kappa enhancer element, transcription is induced and the reporter gene is 
Statistical analysis
Research. The results were expressed as the mean ± SEM of three independent experiments. Statistical significance of the studies was evaluated by the parametric unpaired Student's t test.
Differences with p values ч0.05 are considered significant.
Results
DARPP-32 enhances cell survival of gastric cancer cells
To determine the sensitivity of MKN-28 cells to TRAIL, we employed the clonogenic (25)), we evaluated BCL-xL mRNA and protein expression in the two cell models described above. The qRT-PCR results indicated that the BCL-xL mRNA level was higher in two clones of MKN-28/DARPP-32 cells than control cells (p<0.01) ( Figure 3A ). In agreement with these findings, the knocking down of endogenous DARPP-32 with shRNA alone or in combination with TRAIL treatment led to a significant reduction (p=0.01) in BCL-xL mRNA levels in MKN-45 cells ( Figure   3B ). We also noticed that the increase in the levels of BCL-xL in DARPP-32 cells was more robust at the protein level. The Western blot results showed higher BCL-xL protein levels in the two clones We next examined the role of DARPP-32 in regulating Src/STAT3 signaling pathway.
Western blot data indicated that DARPP-32-induced up-regulation of BCL-xL expression was associated with a significant increase in p-Src(Y416) and p-STAT3(Y705) protein levels as compared to control ( Figure 4D ). In addition, we showed that treatment with PP1 reversed the effects of DARPP-32 on Src/STAT3 signaling and BCL-xL expression ( Figure 4D) . Together, these data demonstrated that the upregulation of BCL-xL via the Src/STAT3 signaling mediates the prosurvival function of DARPP-32 in MKN-28 cells.
DARPP-32 suppresses TRAIL-induced down-regulation of NF-kB activity and FLIP(S) expression
Research. Figure 5C ). These results suggest a direct correlation between TRAIL-induced cleavage of p65 protein and NF-kB activity shown in Figure 5B , and DARPP-32 clearly blocked the effects of TRAIL. Taken together, the data indicated that DARPP-32 sustained nuclear NF-kBp65 protein level, and inhibited its cleavage in response to TRAIL.
Next, we investigated whether cleavage of the p65 protein was dependent on the activation of caspases and the onset of apoptosis. Western blot results showed, as expected, that TRAIL significantly activated caspases 8 and 3, and induced cleavage of the p65 protein ( Figure   5D ). In contrast, z-VAD-fmk inhibitor blocked TRAIL-induced activation of caspases and cleavage of p65 protein in MKN-28 cells ( Figure 5D ). These results demonstrated that TRAIL-induced cleavage of the p65 protein was dependent on activation of caspases.
We also found that TRAIL-induced cleavage of the p65 protein was dependent on the activation of caspases and was associated with a significant decrease in the protein expression of (26)). Although TRAIL could specifically induce tumor cell death, there are many cancer cells that are TRAIL resistant (27) . Resistance to TRAIL is a major clinical challenge that leads to failure of treatment, poor prognosis, and reduced cancer patient survival. Little is known about the mechanisms of TRAIL resistance in gastric cancer. In the current study, we demonstrate a novel signaling mechanism for TRAIL resistance mediated by DARPP-32, which is overexpressed in more than two-thirds of adenocarcinomas of the stomach and esophagus (21, 22) . Given the fact that DARPP-32 is also overexpressed in several other malignancies such as breast and colon cancers, findings from the current study provide novel insight in understanding the complexity of TRAIL resistance which can guide the development of new approaches to circumvent apoptotic blockades or suppress survival signals.
The findings in the present study demonstrated that DARPP-32 promoted cell survival and blocked apoptosis in response to treatment with TRAIL. In an attempt to uncover DARPP-32-mediated signaling mechanism, we found that overexpression of DARPP-32 blocked TRAIL-induced release of cytochrome c and activation of caspases 8, 9, and 3.
Conversely, knockdown of endogenous DARPP-32 enhanced TRAIL-induced activation of caspases 8, 9, and 3. These results suggested that DARPP-32 regulates both the death receptors-mediated extrinsic and the mitochondrial intrinsic apoptosis pathways.
Cytochrome c release occurs in response to several apoptotic stimuli and it is a prerequisite for caspase 9 activation (8, 28) . This implies that DARPP-32-mediated suppression of TRAILinduced activation of the intrinsic apoptosis pathway might involve up-regulated expression shown to protect type II cells against TRAIL-mediated apoptosis (13) . The fact that DARPP-32 up-regulated BCL-xL expression at the protein and mRNA levels through activation of Src/STAT3 signaling, provides a plausible explanation for suppression of the intrinsic apoptosis. Accordingly, DARPP-32-induced up-regulation of BCL-xL may be responsible for blocking TRAIL-mediated cytochrome c release, activation of caspase 9, and subsequently caspase-3. Our finding is in agreement with previous reports that have shown that BCL-xL promotes TRAIL resistance through inhibition of the intrinsic mitochondrial apoptosis pathway in cancer cells (13, 14) . Several reports show that transcription factors such as NFkB and STAT3 could up-regulate BCL-xL in cancer cells (reviewed by Grad et al. (15)). In our MKN-28 cell model, we demonstrated that DARPP-32-induced BCL-xL expression involved activation of STAT3 transcription factor, and excluded a role for NF-kB as a mediator.
Caspase 8 is normally associated with the extrinsic apoptosis pathway, whereby its activation is regulated by the pro-apoptotic molecules (TRAIL, FasL, TNFɲ) or by a negative feedback loop mediated by NF-kB and FLIP (16, 29) . NF-kB activation prevents apoptosis by induction of anti-apoptotic proteins such as BCL-xL, cIAP1&2, xIAP and FLIP (29) (30) (31) (32) (33) . We hypothesized that TRAIL inhibits NF-kB/FLIP signaling, thereby amplifying apoptosis through increased activation of caspase-8. To uncover the signaling mechanism by which DARPP-32 blocks TRAIL-induced activation of caspase 8, we investigated whether the NF-kB/FLIP negative feedback loop was regulated by DARPP-32 in response to TRAIL.
The results indicated that TRAIL-induced apoptosis was accompanied by the inhibition of NF-kB activity, cleavage of NF-kBp65 protein, and down-regulation of FLIP(S) expression. We further confirmed that TRAIL-induced cleavage of the p65 protein and down-regulation of FLIP(S) was dependent on active caspases. This is consistent with the 
-21 -notion that activation of caspases can block NF-kB activity and downstream signaling by inducing cleavage of NF-kBp65 protein (34, 35) . Caspase-mediated cleavage of NF-kBp65 does not simply lead to its inactivation but converts it into a dominant-negative variant of its non-cleaved p65 protein (35) . Although DARPP-32 did not significantly activate NF-kB in basal conditions, it suppressed activation of caspases and maintained NF-kB activity and 
Conflict of interest
The authors declare no conflict of interest. 
